Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | WRN | Q14191 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 2/20 | 0.35 |
| ▸ | FNTB | P49356 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.35 |
| ▸ | MGLL | Q99685 | 5/20 | 0.34 |
| ▸ | FAAH | O00519 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20132349 | 0.88 | FNTA (0.40) | ALDH1A1BLMHPGDCYP1A2CYP2C19 | |
| SCHEMBL20960454 | 0.86 | PTGS1 (0.36) | ALDH1A1HPGDFNTAFNTBPTGS1 | |
| SCHEMBL26645910 | 0.86 | KDM4E (0.44) | ALDH1A1FNTAFNTBPTGS1PTGS2 | |
| SCHEMBL26645911 | 0.86 | KDM4E (0.44) | ALDH1A1FNTAFNTBPTGS1PTGS2 | |
| SCHEMBL17722908 | 0.86 | PTGS1 (0.36) | ALDH1A1HPGDFNTAFNTBPTGS1 | |
| SCHEMBL18932739 | 0.85 | FNTA (0.38) | ALDH1A1HPGDFNTAFNTBPTGS1 | |
| SCHEMBL16006834 | 0.85 | HRH1 (0.36) | ALDH1A1HPGDFNTAFNTBPTGS1 | |
| SCHEMBL20132101 | 0.84 | PTGS1 (0.41) | ALDH1A1HPGDFNTAFNTBPTGS1 | |
| SCHEMBL27415153 | 0.84 | AKT1 (0.36) | ALDH1A1BLMHPGDCYP1A2CYP2C19 | |
| SCHEMBL22668935 | 0.83 | AKT1 (0.35) | ALDH1A1HPGDFNTAFNTBPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021195513-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISORDERS | NOVARTIS AG (CH) | 2021-09-30 | — | — | WO | disclosed |
| US-20200338208-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20190105329-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2019-04-11 | — | — | US | disclosed |
| US-20180126000-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | ABBVIE INC. (US) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180126000-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | ALDH1A1 3434/4885BLM 2995/4885HPGD 1233/4885 |
| US-20190105329-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | ALDH1A1 3611/4885BLM 3658/4885HPGD 4128/4885 |
| US-20200338208-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | NR3C1, NR3C2, MC2R | ALDH1A1 3434/4885BLM 2995/4885HPGD 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.